CV Sciences, Inc. — Third Quarter 2026 Earnings Summary

CV Sciences, Inc. reported third-quarter 2026 revenue of $3.0 million, a 7.0% decrease from the same period in 2025, driven by lower sales volume and average prices due to restrictive federal and state regulations. The company achieved a gross margin of 50.0% and recorded a positive adjusted EBITDA of $32,000, marking a significant improvement over the adjusted EBITDA losses in the prior year and the second quarter of 2026. Operating expenses were reduced by 11.6% year-over-year to $1.6 million, excluding the benefit from a $500,000 gain on a legal settlement. At the end of the quarter, the company held a cash balance of $0.3 million and strengthened its working capital position to $0.7 million.